Bristol-Myers calls off Pixykine deal

Pixykine, Immunex Corp.'s peripatetic molecule in development to boost white blood cell and platelet counts following chemotherapy, has found a new home with American Cyanamid Co.

IMNX (Seattle) had licensed rights to Pixykine outside North America to Bristol-Myers Squibb Co. in 1992 in exchange for rights to 10 generic cancer drugs, including Hydrea (hydroxyurea) and Rubex (doxorubicin). But Bristol-Myers terminated the agreement last week after the companies failed to agree on terms that